Edonerpic maleate

519187-97-4

C20H25NO6S

DMSO : 155 mg/mL (380.39 mM; Need ultrasonic and warming)

Neuronal Signaling

Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-beta peptides (Abeta). IC50 & Target: amyloid-beta peptides^[1] In Vitro: Edonerpic maleate (T-817MA) treatment preserves the cortical neurons in the presence of Abeta(1-42). Twenty-four hours of pretreatment, followed by the continuous presence of Edonerpic maleate, prevents oxidative stress-induced neuronal death at 0.1 and 1 uM. Edonerpic maleate almost completely prevents GSH reduction at 0.1 and 1 uM. Hippocampal slices with 1 uM Edonerpic maleate treatment generate more and much longer neurites than control slices. Edonerpic maleate significantly increases the neurite length at 0.1 and 1 uM^[1]. In Vivo: The post hoc test indicates that the mean density of PSA-positive cells is significantly larger in the vehicle and Abeta infusion+high-dose Edonerpic maleate (T-817MA) groups than that in the Abeta infusion control group (P<0.01). The results indicate that the vehicle and Abeta infusion+high-dose Edonerpic maleate groups display efficient learning in the place learning task (PLT), while these two groups also display vigorous neurogenesis. Treatment with Edonerpic maleate and donepezil does not increase the mean density of normal granule cells; there are no significant differences in the mean granule cell density among the Abeta infusion control, Abeta infusion+high-dose Edonerpic maleate, Abeta infusion+low-dose Edonerpic maleate and Abeta infusion+donepezil groups^[2].